Standardization of measles, mumps and rubella assays to enable comparisons of seroprevalence data across 21 European countries and Australia

Epidemiology and Infection

Volumn 135, Issue 5, 2007, Pages 787-798

  Tischer, A ^a   Andrews, N ^b   Kafatos, G ^b   Nardone, A ^b   Berbers, G ^c   Davidkin, I ^d   Aboudy, Y ^e   Backhouse, J ^f   Barbara, C ^g   Bartha, K ^h   Bruckova, B ⁱ   Ducks, A ^j   Griskevicius, A ^k   Hesketh, L ^l   Johansen, K ^m   Jones, L ⁿ   Kuersteiner, O ^o   Lupulescu, E ^p   Mihneva, Z ^q   Mrazova, M ^r   De Ory, F ^s   Prosenc, K ^t   Schneider, F ^u   Tsakris, A ^v   Smelhausova, M ^r   Vranckx, R ^w   Zarvou, M ^x   Miller, E ^b   more..

^a ROBERT KOCH INSTITUTE   (Germany)

^b PUBLIC HEALTH ENGLAND   (United Kingdom)

^c NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^d NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^e SHEBA MEDICAL CENTER   (Israel)

^f NATIONAL CENTRE FOR IMMUNISATION RESEARCH AND SURVEILLANCE   (Australia)

^g ST LUKE S HOSPITAL   (Malta)

^h NATIONAL CENTER FOR EPIDEMIOLOGY   (Hungary)

ⁱ Department of Environment and Health   (Slovakia)

^j Public Health Agency   (Latvia)

^k Lithuanian AIDS Centre   (Lithuania)

^l Preston Public Health Laboratory   (United Kingdom)

^m SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

ⁿ National Virology Laboratory   (Ireland)

^o Berna Biotech AG   (Switzerland)

^p NATIONAL INSTITUTE FOR RESEARCH AND DEVELOPMENT IN MICROTECHNOLOGIES   (Romania)

^q NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES   (Bulgaria)

^r NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^s INSTITUTO DE SALUD CARLOS III   (Spain)

^t NATIONAL INSTITUTE OF PUBLIC HEALTH   (Slovenia)

^u LABORATOIRE NATIONAL DE SANTÉ   (Luxembourg)

^v UNIVERSITY OF ATHENS   (Greece)

^w SCIENTIFIC INSTITUTE OF PUBLIC HEALTH   (Belgium)

^x NICOSIA GENERAL HOSPITAL   (Cyprus)

more..

Author keywords

[No Author keywords available]

Indexed keywords

MEASLES ANTIBODY; RUBELLA ANTIBODY; VIRUS ANTIBODY;

ANTIBODY DETECTION; ARTICLE; AUSTRALIA; CHILD; CONTROLLED STUDY; DATA ANALYSIS; DISEASE SURVEILLANCE; ENZYME IMMUNOASSAY; EUROPE; GEOGRAPHIC DISTRIBUTION; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEASLES; MUMPS; NONHUMAN; QUALITATIVE DIAGNOSIS; REFERENCE VALUE; RUBELLA; SENSITIVITY AND SPECIFICITY; SEROPREVALENCE; STANDARDIZATION; VIRUS DETECTION; VIRUS NEUTRALIZATION;

EID: 34547465803     PISSN: 09502688     EISSN: 14694409     Source Type: Journal    
DOI: 10.1017/S0950268807008266     Document Type: Article

References (33)

1. Matter L, et al. Age-stratified seroprevalence of measles, mumps and rubella (MMR) virus infections in Switzerland after introduction of MMR mass vaccination. European Journal of Epidemiology 1997; 13: 61-63.
2. Janaszek W, Gut W, Gay NJ. The epidemiology of measles in Poland: prevalence of measles virus antibodies in the population. Epidemiology and Infection 2000; 125: 385-392.
3. Osborne K, et al. Ten years of serological surveillance in England and Wales: Methods, results, implications and action. International Journal of Epidemiology 2000; 29: 362-368.
4. Gabutti G, et al. Epidemiology of measles, mumps and rubella in Italy. Epidemiology and Infection 2002: 129: 543-550.
5. Chiu H-H, et al. Seroepidemiological study of measles after the 1992 nationwide MMR revaccination program in Taiwan. Journal of Medical Virology 1997; 51: 32-35.
6. Gilbert GL, et al. Impact of the Australian measles control campaign on immunity to measles and rubella. Epidemiology and Infection 2001; 127: 297-303.
7. Kim S-S, et al. Sero-epidemiology of measles and mumps in Korea: Impact of the catch-up campaign on measles immunity. Vaccine 2004; 23: 290-297.
8. Osborne K, Weinburg J, Miller E. The European Seroepidemiology Network. Eurosurveillance 1997; 2: 29-31.
9. Ratnam S, et al. Comparison of commercial enzyme immunoassay kits with plaque reduction neutralisation test for detection of measles virus antibody. Journal of Clinical Microbiology 1995; 33: 811-815.
10. Hesketh L, et al. An evaluation of nine commercial EIA kits for the detection of measles specific IgG. Journal of Virological Methods 1997; 66: 51-59.
11. Andrews N, et al. The European Sero-Epidemiological Network: standardizing the enzyme immunoassay results for measles, mumps and rubella. Epidemiology and Infection 2000; 125: 127-143.
12. Kafatos G, Andrews N, Nardone A. Model selection methodology for inter-laboratory standardisation of antibody titres. Vaccine 2005; 23: 5022-5027.
13. Dopatka HD, Giesendorf B. Single point quantification of antibody by ELISA without need of a reference curve. Journal of Clinical and Laboratory Analysis 1992; 6: 417-422.
14. Tischer A, Gerike E. Immune response after primary and re-vaccination with different combined vaccines against measles, mumps, rubella. Vaccine 2000; 18: 1382-1392.
15. Anon. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: 'Text on Validation of Analytical Procedures Q2a' (http://www.ich.org/LOB/media/ MEDIA417.pdf). Accessed 6 November 1996.
16. Anon. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use: 'Validation of Analytical Procedures: Methodology Q2b' (http://www.ich.org/LOB/media/MEDIA417.pdf). Accessed 6 November 1996.
17. Standardisation Results - European Sero-Epidemiology Network 2 (http://www.hpa.org.uk/hpa/inter/esen2_results.htm). Accessed 27 April 2006.
18. Örvell C, et al. Characterisation of genotype specific epitopes of the HN protein of mumps virus. Journal of General Virology 1997; 78: 3187-3193.
19. Muhlemann K. The molecular epidemiology of mumps virus. Infection Genetics and Evolution 2004; 4: 215-219.
20. Albrecht P, Herrmann K, Burns GR. Role of virus strain in conventional and enhanced measles plaque neutralization test. Journal of Virological Methods 1981; 3: 251-260.
21. Chen RT, et al. Measles antibody: Reevaluation of protective titres. Journal of Infectious Diseases 1990; 162: 1036-1042.
22. Lee MS, et al. Protective titres of measles neutralising antibody. Journal of Medical Virology 2000; 62: 511-517.
23. Berger R, Just M. Comparison of five different tests for mumps antibodies. Infection 1980; 8: 180-183.
24. Sakata H, Hishiyama M, Sugiura A. Enzyme-linked immunosorbent assay compared with neutralization tests for evaluation of live mumps vaccines. Journal of Clinical Microbiology 1984; 19: 21-25.
25. Linde GA, Granström M, Örvell C. Immunoglobulin class and immunoglobulin G subclass enzyme-linked immunosorbent assays compared with microneutralization assay for serodiagnosis of mumps infection and determination of immunity. Journal of Clinical Microbiology 1987; 25: 1653-1658.
26. Pipkin PA, et al. Assay of humoral immunity to mumps virus. Journal of Virological Methods 1999; 79: 219-225.
27. Fedova D, et al. Detection of postvaccination mumps virus antibody by neutralization test, enzyme-linked immunosorbent assay and sensitive hemagglutination inhibition test. Journal of Hygiene, Epidemiology, Microbiology and Immunology 1987; 31: 409-422.
28. Christensen B, Böttiger M. Methods for screening the naturally aquired and vaccine-induced immunity to the mumps virus. Biologicals 1990; 18: 213-219.
29. Frankova V, et al. Contribution to laboratory diagnosis of mumps and parainfluenza. Acta Virologica 1988; 32: 503-514.
30. Harmsen T, et al. Comparison of neutralization enzyme immunoassay and enzyme-linked immuno-sorbent assay for evaluation of the immune status of mumps vaccinated children. Journal of Clinical Microbiology 1992; 30: 2139-2144.
31. Skendzel LP. Rubella immunity. Defining the level of protective antibody. American Journal of Clinical Pathology 1996; 106: 170-174.
32. Matter L, Kogelschatz K, Germann D. Serum levels of rubella virus antibodies indicating immunity: Response to vaccination of subjects with low or undetectable antibody concentrations. Journal of Infectious Diseases 1997; 175: 749-755.
33. Davidkin I, et al. Duration of rubella immunity induced by two-dose measles, mumps and rubella (MMR) vaccination. A 15-year follow-up in Finland. Vaccine 2000; 18: 3106-3112.